^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?

Published date:
09/07/2020
Excerpt:
Interestingly, in this subgroup, patients had a significantly lower 5-year EFS compared to patients without expression of HER2/neu (63,0% versus 80,5%, p=0.02). In conclusion, these 4 antigens could be alternatives of interest especially since CD19 can be downmodulated after current therapies targeting this antigen. Trastuzumab could also be a potential interesting immunotherapy in the HER2/neu expressing group, especially in relapsed childhood ALL.
DOI:
10.1002/hon.2799